Contact
searchSearch
HMP Global

Dermatology

News
Treatment Switching Associated With Increased Health Care Utilization and Costs Among Patients With AD
10/21/2026
Rebecca Amrick
Researchers found that among patients with moderate to severe atopic dermatitis (AD), those who switched to second-line therapies had higher utilization rates and care costs compared to those who remained on first-line treatments.
Researchers found that among patients with moderate to severe atopic dermatitis (AD), those who switched to second-line therapies had higher utilization rates and care costs compared to those who remained on first-line treatments.
Researchers found that among...
10/21/2026
First Report Managed Care
News
Ruxolitinib Cream Improves Moderate Atopic Dermatitis After Prior Topical Treatment Failure
10/08/2026
Hannah Musick
In the phase 3 TRuE-AD4 trial, ruxolitinib cream significantly improved disease severity, itch, and quality of life among adults with moderate atopic dermatitis who had not responded adequately to conventional topical therapies, potentially...
In the phase 3 TRuE-AD4 trial, ruxolitinib cream significantly improved disease severity, itch, and quality of life among adults with moderate atopic dermatitis who had not responded adequately to conventional topical therapies, potentially...
In the phase 3 TRuE-AD4 trial,...
10/08/2026
First Report Managed Care
News
Outpatient Care Patterns Among Patients With Vitiligo
09/29/2026
Rebecca Amrick
Researchers assessed outpatient vitiligo care among US adults and found that most visits were with dermatologists or primary care physicians, with topical corticosteroids emerging as the most common treatment.
Researchers assessed outpatient vitiligo care among US adults and found that most visits were with dermatologists or primary care physicians, with topical corticosteroids emerging as the most common treatment.
Researchers assessed outpatient...
09/29/2026
First Report Managed Care
News
US Vitiligo Study Finds Short Treatment Duration, Variable Care Patterns
09/18/2026
Grace Taylor, MS, MA
A study found that US patients with vitiligo showed short treatment durations and highly variable treatment patterns, while approximately one-third received no treatment following diagnosis.
A study found that US patients with vitiligo showed short treatment durations and highly variable treatment patterns, while approximately one-third received no treatment following diagnosis.
A study found that US patients...
09/18/2026
First Report Managed Care
News
The Impact of Atopic Comorbidities on Health Care Utilization for Atopic Dermatitis
09/15/2026
Rebecca Amrick
New research suggests an association between atopic comorbidities and health care utilization and costs among young children with atopic dermatitis.
New research suggests an association between atopic comorbidities and health care utilization and costs among young children with atopic dermatitis.
New research suggests an...
09/15/2026
First Report Managed Care
News
Real-World Abrocitinib Use Shows Stable Dosing in US Patients With Atopic Dermatitis
09/08/2026
Grace Taylor, MS, MA
A US real-world study found that most patients with atopic dermatitis initiated abrocitinib at 100 mg and maintained their starting dose for up to 12 months.
A US real-world study found that most patients with atopic dermatitis initiated abrocitinib at 100 mg and maintained their starting dose for up to 12 months.
A US real-world study found that...
09/08/2026
First Report Managed Care
News
The Treatment Landscape and Economic Burden of Chronic Hand Eczema
08/27/2026
Rebecca Amrick
Researchers evaluated treatment patterns and care costs among patients with chronic hand eczema, outlining varied disease presentation, extensive use of corticosteroids, and care costs that increase with treatment intensity.
Researchers evaluated treatment patterns and care costs among patients with chronic hand eczema, outlining varied disease presentation, extensive use of corticosteroids, and care costs that increase with treatment intensity.
Researchers evaluated treatment...
08/27/2026
First Report Managed Care
News
Promoting Equitable Care Among Patients With Atopic Dermatitis
08/21/2026
Rebecca Amrick
In a panel hosted by the Academy of Managed Care Pharmacy (AMCP) Market Insights, experts in dermatology and managed care discussed various health disparities for patients with moderate to severe atopic dermatitis, suggesting strategies and...
In a panel hosted by the Academy of Managed Care Pharmacy (AMCP) Market Insights, experts in dermatology and managed care discussed various health disparities for patients with moderate to severe atopic dermatitis, suggesting strategies and...
In a panel hosted by the Academy...
08/21/2026
First Report Managed Care
News
JAK Inhibitors Demonstrate Improved Efficacy Among Various Skin Conditions
08/18/2026
Rebecca Amrick
A systematic review of clinical trials examining the impact of Janus kinase (JAK) inhibitors on skin conditions found that they demonstrated higher efficacy and comparable safety when compared with a placebo.
A systematic review of clinical trials examining the impact of Janus kinase (JAK) inhibitors on skin conditions found that they demonstrated higher efficacy and comparable safety when compared with a placebo.
A systematic review of clinical...
08/18/2026
First Report Managed Care
News
Emerging Research Supports Nonsteroidal Therapies in Pediatric Dermatology
08/12/2026
Rebecca Amrick
Recent research demonstrates the safety and effectiveness of nonsteroidal topical therapies for a variety of pediatric skin conditions, suggesting a possible shift away from traditional corticosteroid treatments.
Recent research demonstrates the safety and effectiveness of nonsteroidal topical therapies for a variety of pediatric skin conditions, suggesting a possible shift away from traditional corticosteroid treatments.
Recent research demonstrates the...
08/12/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use